Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
Orasure Technologies Inc Schedule 13G filed reporting aggregate beneficial ownership figures for Neil Gagnon and entities he controls. The filing lists Neil Gagnon with 3,754,846 shares (5.4%), Gagnon Securities LLC with 1,929,799 shares (2.8%), and Gagnon Advisors, LLC with 1,207,440 shares (1.7%). The percent calculations are based on 69,126,173 shares outstanding as of February 28, 2026. The filing states that Gagnon and the advisory entities may be deemed to share voting and dispositive power over these accounts and that the advisers expressly disclaim beneficial ownership of securities held in client accounts.
OraSure Technologies director Steven Kyle Boyd reported routine equity compensation activity. He received a grant of 5,246 shares of common stock at $3.0975 per share value under the company’s Stock Award Plan, with immediate vesting and issued in lieu of cash director fees.
To cover taxes on the vesting, 1,416 shares were withheld, a non-market disposition used to pay the related tax liability. After these transactions, Boyd directly owns 38,462 shares of OraSure common stock. The filing reflects standard board compensation rather than open-market buying or selling.
OraSure Technologies furnished an investor presentation addressing its business performance, governance and engagement with Altai Capital ahead of the 2026 annual meeting. The company highlights a focused diagnostics strategy, expecting revenue growth, margin expansion and operating cash flow breakeven in the first half of 2026.
Management points to stabilizing public health funding, planned launches of the Colli-Pee urine collection device and Sherlock CT/NG self-test, and a strong balance sheet with $199 million cash and no debt. A $40 million share repurchase program began in 2025, with $15 million already deployed at an average price of $2.85. The presentation also shows 2025 non‑GAAP gross margin of 42.6% on revenue of $115,021, compared with 39.9% on $387,479 in 2022, and discusses non‑GAAP measures and extensive forward‑looking risks.
OraSure Technologies Inc: Amendment No. 10 to a Schedule 13G/A discloses that The Vanguard Group reports 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report disaggregated ownership separately in reliance on SEC Release No. 34-39538.
The form lists Vanguard's address and notes the filing was signed by Ashley Grim, Head of Global Fund Administration on 03/27/2026. The filing classifies this holding as ownership of 5 percent or less.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 32,300 shares of common stock. The trade occurred on March 20, 2026 at a weighted average price of $2.9288 per share, with individual prices ranging from $2.86 to $2.98.
After this transaction, McGrath directly holds 589,562 OraSure shares. The purchase was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 28, 2025, indicating the buying activity was scheduled in advance rather than timed discretionarily.
OraSure Technologies President & CEO Carrie Eglinton-Manner bought 32,300 shares of common stock in an open-market transaction. The shares were purchased on March 20, 2026 at a weighted average price of $2.9287 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025.
After this purchase, she directly owns 2,190,874 OraSure shares. The filing notes the shares were acquired through multiple trades within a price range of $2.86 to $2.98 per share.
OraSure Technologies senior vice president of finance and chief accounting officer Anthony Michele Marie reported routine equity compensation activity in common stock. On March 2, 2026, she received a grant of 42,982 shares of restricted stock that vest in three equal annual installments beginning on March 2, 2027, contingent on continued service.
On March 1, 2026, she acquired 14,183 shares in settlement of vested performance units, then had 4,062 shares and 10,817 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly held 185,788 shares of OraSure common stock.
OraSure Technologies received an amended Schedule 13D from Altai Capital, led by Rishi Bajaj, reflecting an activist position. The reporting persons beneficially own 3,613,836 shares of common stock, representing 5.2% of the company based on 69,126,173 shares outstanding as of February 28, 2026.
On March 17, 2026, Altai Capital’s investment manager issued a press release with an open letter to the board outlining its case for change and reiterating its intention to solicit proxies to elect Rishi Bajaj and John Bertrand at the annual meeting. The full letter is filed as Exhibit 99.3.
Altai Capital, a shareholder owning approximately 5% of OraSure Technologies (OSUR), has filed a Schedule 14A nominating Rishi Bajaj and John Bertrand for the 2026 Annual Meeting and delivered a letter urging board change. Altai cites chronic underperformance (stock declines of 67% and 56% on 5- and 10-year bases as of 03/06/26), management compensation misalignment (an estimated $15 million earned by the CEO over her tenure), and capital allocation decisions including a $30 million investment in Sapphiros and a Sherlock Biosciences acquisition with contingent payments.
Altai requests a strategic review including consideration of a sale, seeks board seats for its nominees, and says it will solicit votes if no settlement is reached.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 22,021 shares of common stock. The shares were bought on March 13, 2026 at a weighted average price of $2.9985 per share, in multiple trades between $2.93 and $3.12. Following this transaction, he directly owns 557,262 shares. The purchase was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2025.